Current Report Filing (8-k)
February 26 2019 - 8:56AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported):
February 26, 2019
Nexien
BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Commission
File No.:
0-55320
Delaware
|
|
26-2049376
|
(State
or other jurisdiction of incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
|
|
|
4340
E Kentucky Ave, Suite 206, Glendale, CO
|
|
80246
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (303) 495-7583
Not
applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Exchange Act of 1934. Emerging growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01 Regulation FD Disclosure.
On
February 26, 2019, Nexien BioPharma, Inc. issued a press release about its intention to commence pre-clinical and clinical studies
of cannabinoid formulations in the treatment of patients suffering from myotonic dystrophies. This Form 8-K and the information
included as exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (“Exchange Act”), nor shall it be incorporated by reference into a filing under the Securities Act
of 1933, as amended (“Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in
such a filing. The furnishing of the information in this report is not intended to, and does not, constitute a determination or
admission by the Company that the information in this report is material or complete, or that investors should consider this information
before making an investment decision with respect to any security of the Registrant or any of its affiliates.
Item
9.01 Financial Statements and Exhibits.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
NEXIEN
BIOPHARMA, INC.
/s/:
Alex Wasyl
|
|
Alex
Wasyl, Chief Executive Officer
February
26, 2019
|
|
EXHIBIT
INDEX
Nexien BioPharma (QB) (USOTC:NXEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nexien BioPharma (QB) (USOTC:NXEN)
Historical Stock Chart
From Apr 2023 to Apr 2024